Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone

被引：48
|
作者：
Leung, Nelson [1 ,2 ]
Thome, Stephan D. [3 ]
Dispenzieri, Angela [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA
[2] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN 55905 USA
[3] Mayo Clin, Div Med Oncol, Rochester, MN USA
来源：
HAEMATOLOGICA | 2018年 / 103卷 / 03期
关键词：
MONOCLONAL GAMMOPATHY; AL AMYLOIDOSIS; THERAPY; TRANSLOCATION; SURVIVAL; T(11/14); MYELOMA;
D O I：
10.3324/haematol.2017.183749
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E135 / E137
页数：3
相关论文
共 50 条
  • [31] Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone +/- daratumumab: Results from the ANDROMEDA study
    Sanchorawala, Vaishali
    Palladini, Giovanni
    Minnema, Monique C.
    Jaccard, Arnaud
    Lee, Hans C.
    Gibbs, Simon
    Mollee, Peter
    Venner, Christopher
    Lu, Jin
    Schonland, Stefan
    Gatt, Moshe
    Suzuki, Kenshi
    Kim, Kihyun
    Cibeira, Maria Teresa
    Beksac, Meral
    Libby, Edward
    Valent, Jason
    Hungria, Vania
    Wong, Sandy W.
    Rosenzweig, Michael
    Bumma, Naresh
    Chauveau, Dominique
    Gries, Katharine S.
    Fastenau, John
    Tran, Nam Phuong
    Qin, Xiang
    Vasey, Sandra Y.
    Weiss, Brendan M.
    Vermeulen, Jessica
    Ho, Kai Fai
    Merlini, Giampaolo
    Comenzo, Raymond L.
    Kastritis, Efstathios
    Wechalekar, Ashutosh D.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (06) : 719 - 730
  • [32] Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes
    Diaz-Pallares, Carolina
    Lee, Holly
    Luider, Joanne
    Duggan, Peter
    Neri, Paola
    Tay, Jason
    MacCulloch, Sylvia
    Bahlis, Nizar J.
    Jimenez-Zepeda, Victor H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (06): : 394 - 399
  • [33] Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial
    Shen, Kai-Ni
    Fu, Wei-Jun
    Wu, Yu
    Dong, Yu-Jun
    Huang, Zhong-Xia
    Wei, Yong-Qiang
    Li, Chun-Rui
    Sun, Chun-Yan
    Chen, Ye
    Miao, Hui-Lei
    Zhang, Yue-Lun
    Cao, Xin-Xin
    Zhou, Dao-Bin
    Li, Jian
    CIRCULATION, 2022, 145 (01) : 8 - 17
  • [34] Venetoclax Plus CyBorD Induction Therapy and Venetoclax Maintenance Treatment for Immunoglobulin Light Chain Amyloidosis with t(11;14) Translocation
    Garami, Greta
    Obajed Al-Ali, Omar
    Virga, Istvan
    Gulyas, Anita
    Bedekovics, Judit
    Tornai, Istvan
    Illes, Arpad
    Magyari, Ferenc
    CURRENT ONCOLOGY, 2025, 32 (02)
  • [35] Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a Diverse Patient Population with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius
    Rosenzweig, Michael
    Efebera, Yvonne
    Kastritis, Efstathios
    Blue, Brandon
    Jamal, Faizi
    Minnema, Monique C.
    Pericone, Christopher
    Vasey, Sandra
    Chen, Yuping
    Kotoulek, Sonja
    Vandael, Bart
    Duran, Joana
    Khaled, Samer
    NamPhuong Tran
    Vermeulen, Jessica
    Sanchorawala, Vaishali
    BLOOD, 2023, 142
  • [36] Successful Treatment of Amyloid Light-chain Amyloidosis in a Charcot-Marie-Tooth Disease Patient with Lenalidomide, Cyclophosphamide, and Dexamethasone
    Kikukawa, Yoshitaka
    Hata, Hiroyuki
    Ueda, Mitsuharu
    Yamashita, Taro
    Nasu, Singo
    Ide, Kazuhiko
    Ueno, Shikiko
    Ando, Yukio
    Mitsuya, Hiroaki
    Okuno, Yutaka
    INTERNAL MEDICINE, 2016, 55 (18) : 2707 - 2712
  • [37] Bortezomib-induced cardiogenic shock in a multiple myeloma patient with K light-chain cardiac amyloidosis
    Valentino Dammassa
    Alessandra Greco
    Rossana Totaro
    Costanza Natalia Julia Colombo
    Claudia Raineri
    Rita Camporotondo
    Gaetano Maria De Ferrari
    Francesco Mojoli
    Eloisa Arbustini
    Luigi Oltrona Visconti
    Guido Tavazzi
    Annals of Hematology, 2022, 101 : 2087 - 2088
  • [38] Bortezomib-induced cardiogenic shock in a multiple myeloma patient with K light-chain cardiac amyloidosis
    Dammassa, Valentino
    Greco, Alessandra
    Totaro, Rossana
    Colombo, Costanza Natalia Julia
    Raineri, Claudia
    Camporotondo, Rita
    De Ferrari, Gaetano Maria
    Mojoli, Francesco
    Arbustini, Eloisa
    Oltrona Visconti, Luigi
    Tavazzi, Guido
    ANNALS OF HEMATOLOGY, 2022, 101 (09) : 2087 - 2088
  • [39] Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis
    Muchtar, Eli
    Gertz, Morie A.
    Laplant, Betsy
    Buadi, Francis K.
    Leung, Nelson
    Peterson, Stephanie M.
    Bergsagel, P. Leif
    Fonder, Amie
    Hwa, Yi L.
    Hobbs, Miriam A.
    Helgeson, Dania Kaehlyn
    Vossen, Alanna M.
    Gonsalves, Wilson I.
    Lacy, Martha Q.
    Kapoor, Prashant
    Siddiqui, Mustaqeem A.
    Larsen, Jeremy
    Warsame, Rahma M.
    Hayman, Suzanne R.
    Go, Ronald S.
    Dingli, David
    Kourelis, Taxiarchis
    Dispenzieri, Angela
    Md, S. Vincent Rajkumar
    Kumar, Shaji K.
    BLOOD, 2020, 136
  • [40] Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL)
    Dispenzieri, Angela
    Dasari, Surendra
    Arendt, Bonnie Kaye
    Kohlhagen, Mindy Kohlhagen
    Kourelis, Taxiarchis
    Gertz, Morie A.
    Kumar, Shaji K.
    Rajkumar, S. Vincent
    Buadi, Francis K.
    Dingli, David
    Leung, Nelson
    Kapoor, Prashant
    Go, Ronald S.
    Kyle, Robert A.
    Muchtar, Eli
    Hwa, Yi
    Warsame, Rahma
    Gonsalves, Wilson I.
    Zeldenrust, Steven
    Fonder, Amie
    Hobbs, Miriam
    Lust, John A.
    Russell, Stephen J.
    Murray, David L.
    BLOOD, 2018, 132
12345